The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

KRAS GTPases are activated in one-third of cancers, and KRAS (G12C) is one of the most
common activating alterations in lung adenocarcinoma,. KRAS (G12C) inhibitors, are in …

Abstract Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive
histologic subtype of prostate cancer that most commonly arises in later stages of prostate …

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching
rules that supersede variability. Here, we define pan-cancer binary classes based on distinct …

Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in
hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not
classically “druggable,” including loss-of-function mutations in tumor suppressor genes …

Progression through G1/S phase of the cell cycle is coordinated by cyclin-dependent kinase
(CDK) activities. Here, we find that the requirement for different CDK activities and cyclins in …